Peramivir: evidence to support the use of the first approved intravenous therapy for influenza
Peramivir: evidence to support the use of the first approved intravenous therapy for influenza
About this item
Full title
Author / Creator
Publisher
London: Future Medicine Ltd
Journal title
Language
English
Formats
Publication information
Publisher
London: Future Medicine Ltd
Subjects
More information
Scope and Contents
Contents
Peramivir, an intravenous neuraminidase inhibitor, was first available in clinical practice during the 2009 A/H1N1 pandemic under an Emergency Use Authorization by the US FDA. As the lone intravenous neuraminidase inhibitor available and with a novel structure compared with the available neuraminidase inhibitors, it was offered as an alternative to...
Alternative Titles
Full title
Peramivir: evidence to support the use of the first approved intravenous therapy for influenza
Authors, Artists and Contributors
Author / Creator
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_journals_1714308810
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_1714308810
Other Identifiers
ISSN
1746-0794
E-ISSN
1746-0808
DOI
10.2217/FVL.15.61
